Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Brett P. Monia Sells 2,285 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Free Report) CEO Brett P. Monia sold 2,285 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $51.75, for a total transaction of $118,248.75. Following the completion of the sale, the chief executive officer now owns 151,851 shares in the company, valued at $7,858,289.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ionis Pharmaceuticals Trading Down 0.2 %

NASDAQ IONS opened at $51.90 on Wednesday. Ionis Pharmaceuticals, Inc. has a 12 month low of $32.69 and a 12 month high of $54.44. The company has a 50-day moving average of $50.75 and a 200-day moving average of $45.91. The company has a debt-to-equity ratio of 4.06, a current ratio of 6.39 and a quick ratio of 6.33. The company has a market cap of $7.45 billion, a P/E ratio of -18.08 and a beta of 0.47.

Ionis Pharmaceuticals (NASDAQ:IONSGet Free Report) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02). The business had revenue of $144.00 million during the quarter, compared to analyst estimates of $139.42 million. Ionis Pharmaceuticals had a negative return on equity of 90.50% and a negative net margin of 66.34%. As a group, equities analysts predict that Ionis Pharmaceuticals, Inc. will post -3.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on IONS shares. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, December 19th. Stifel Nicolaus upped their price target on shares of Ionis Pharmaceuticals from $45.00 to $50.00 and gave the company a “hold” rating in a research note on Monday, December 18th. Morgan Stanley upped their price objective on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, The Goldman Sachs Group increased their price objective on shares of Ionis Pharmaceuticals from $25.00 to $28.00 and gave the company a “sell” rating in a report on Friday, November 3rd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $49.43.

Get Our Latest Report on IONS

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Tennessee Valley Asset Management Partners bought a new stake in Ionis Pharmaceuticals in the fourth quarter worth about $34,000. Peoples Bank KS purchased a new position in Ionis Pharmaceuticals in the 3rd quarter worth about $39,000. Almanack Investment Partners LLC. purchased a new position in Ionis Pharmaceuticals during the 3rd quarter valued at about $44,000. Quantbot Technologies LP purchased a new position in Ionis Pharmaceuticals during the 2nd quarter valued at about $44,000. Finally, Captrust Financial Advisors lifted its holdings in shares of Ionis Pharmaceuticals by 21.1% during the 2nd quarter. Captrust Financial Advisors now owns 1,429 shares of the company’s stock valued at $53,000 after buying an additional 249 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

See Also

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.